HAYWARD，Calif.--（BUSINESS WIRE）--Reflexion Medical，a therapeutic oncology company pioneering the use of biology-guided radiotherapy（BgRT）*for all stages of cancer，today announced that researchers will present new data from 14 medical physics investigations validating the efficacy and feasibility of the RefleXion®X1 radiotherapy platform with and without BgRT at the 2022 American Association of Physicists in Medicine（AAPM）Annual Meeting in Washington，D.C.，July10-14。

Two of the 14abstracts are oral presentations，one of which was selected as“Best in Physics，”adistinction granted to only15abstracts by the AAPM。The company is showcasing the X1radiotherapy platform and future BgRT capabilities in booth#5093。

Reflexion is also hosting an industry lunch symposium during the AAPM annual meeting at12:45pm EDT today.Titled“Preparing for Biology-guided Radiotherapy in the Clinic，”the symposium features a presentation on BgRT and advantages for eliminating challenges with motion management by Murato Surucu，Ph.D.，as well as a presentation on BgRT commissioning and workflow by Nataliya Kovalchuk，Ph.D.，based on their facility’s experience participating in RefleXion’s Investigational Device Exemption（IDE）clinical study。

“We are extremely encouraged by the growing body of scientific evidence validating the Reflexion X1platform，the future potential of BgRT，and its impact on workflow and treatment planning，”said Sean Shirvani，M.D.，chief medical officer of RefleXion，including an oral presentation that earned the distinction‘Best in Physics，’further underscores our commitment to achieving and surpassing industry standards of quality radiotherapy treatments for patients.”

The following tworal presentations and two poster presentations high light some of the new research being shared regarding the use of BgRT for treatment planning for various anatomic sites，time savings，and simplification in workflow:

原始预设：

• “Investigation of computation time and storage savings using Generative Adversarial Network（GAN）source models for dose simulation of a binary MLC Lina，” presented by Bin Han，Ph.D.，Sunday，July10from4:00pm–5:00pm EDT.This study investigated the feasibility of Generative Adversarial Network（GAN）in modeling the Reflexion X1 Linac by replacing each collimated beam with a GAN generator for Monte Carlo simulation。

• “Biology Guided Radiation Therapy，” 第一个在Physics and presented by Guillem Pratx，Ph.D.，Thursday，July14，from7:30am–8:30am EDT。 This study investigated whether a long-lived PET isotope tagged with antibody（immune-PET）could simplify the BgRT workflow by reducing the multiple tracer injections while improving tumor-specific uptake and guidance。

后期准备：

• “One-year quality assurance experience of the first Reflexion system，”presented by Murat Surucu，Ph.D.，Tuesday，July12，from1:15pm–1:45pm EDT.This study reports on the daily，monthly，and annual quality assurance（QA）measurement results of the first clinical BgRT capable machine following the AAPMTG-148protocol。

• “Biology Guided Radiotherapy（BgRT）treatment planning feasibility study for head-and-neck，abdomen，and pelvis，”presented by Nataliya Kovalchuk，Ph.D.，Tuesday，July12 from3:45pm–4:15pm EDT.The purpose of this study was to evaluate the feasibility of BgRT treatment planning for various treatment sites in five cancer patients。

About Reflexion Medical

反射，反射 is a privately-held company developing the first biology-guided radiotherapy system，a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in cancers thave metasized.Currently，the RefleXion X1machine is cleared for the delivery of ebootic radioty，SBapy，stereotactic radiosurgery（SRS）and intensity modulated radiotherapy（IMRT）。The company is also developing BgRT，which incorporates positron-emission tomography（PET）imaging data to enable tumors to continuously signal their location。The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency。

*The Reflexion®X1 is cleared for SBRT/SRS/IMRT.BgRT is pending regulatory review and is not commercially available。

查看source version on businesswire.com：https://www.businesswire.com/news/home/20220711005223/en/